MassMutual Private Wealth & Trust FSB Sells 3,190 Shares of Stryker Corporation $SYK

MassMutual Private Wealth & Trust FSB lessened its holdings in Stryker Corporation (NYSE:SYK) by 4.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,936 shares of the medical technology company’s stock after selling 3,190 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Stryker were worth $20,759,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Confluence Investment Management LLC raised its holdings in Stryker by 1.9% during the second quarter. Confluence Investment Management LLC now owns 212,000 shares of the medical technology company’s stock worth $66,746,000 after acquiring an additional 3,941 shares in the last quarter. First Financial Bank Trust Division grew its stake in Stryker by 2.1% in the second quarter. First Financial Bank Trust Division now owns 35,165 shares of the medical technology company’s stock valued at $11,071,000 after purchasing an additional 724 shares in the last quarter. Eastern Bank increased its position in shares of Stryker by 7.9% during the 2nd quarter. Eastern Bank now owns 3,879 shares of the medical technology company’s stock worth $1,221,000 after purchasing an additional 285 shares during the last quarter. Ballast Advisors LLC raised its stake in shares of Stryker by 2.5% during the 1st quarter. Ballast Advisors LLC now owns 4,185 shares of the medical technology company’s stock worth $1,375,000 after purchasing an additional 104 shares in the last quarter. Finally, FAS Wealth Partners Inc. bought a new stake in shares of Stryker during the 1st quarter worth approximately $244,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $340.73 on Tuesday. The firm’s 50 day simple moving average is $317.77 and its 200 day simple moving average is $334.62. The firm has a market capitalization of $130.62 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 2.08 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts expect that Stryker Corporation will post 15.01 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend was Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup restated an “outperform” rating on shares of Stryker in a research note on Monday. Needham & Company LLC cut their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and set a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. BTIG Research decreased their target price on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a report on Friday. Finally, Wolfe Research set a $375.00 price target on Stryker in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.